Skip to content

Clinical application of different doses of rimazole in painless gastroenteroscopy

Clinical application of different doses of rimazole in painless gastroenteroscopy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053925
Enrollment
Unknown
Registered
2021-12-02
Start date
2021-12-31
Completion date
Unknown
Last updated
2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroenteroscopy diagnosis and treatment

Interventions

Group 2:Rimazolam 0.1mg/kg
Group 3:Rimazolam 0.2mg/kg
Group 4:Rimazolam 0.3mg/kg

Sponsors

Affiliated Hospital of Chengdu University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: In this study, patients aged 18 to 65 years without serious systemic diseases were selected.

Exclusion criteria

Exclusion criteria: 1. The number of additional drugs more than 5 times within 15min; 2. Patients who conceal past medical history and have an influence on the adverse reaction records, such as Meniere's syndrome, etc.; 3. Patients with severe heart and lung function diseases, severe liver and kidney dysfunction, coagulation disorders, severe anemia, severe malnutrition, severe lung infection, etc., as well as patients with autoimmune diseases and those who have taken immunosuppressive drugs.

Design outcomes

Secondary

MeasureTime frame
systolic blood pressure;Heart rate;blood oxygen saturation;Endoscopy time;Recovery time after drug withdrawal;Departure time;Drug dosage;nausea;vomit;Incidence of respiratory depression;

Countries

China

Contacts

Public ContactJiang Min

Affiliated Hospital of Chengdu University

176846022@qq.com+86 13882120714

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026